Neuroprotective strategies for Parkinson's disease

Current Neuropharmacology

Volumn 2, Issue 3, 2004, Pages 309-322

  Cantuti Castelvetri, Ippolita ^a   Standaert, David G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMANTADINE; ANTIOXIDANT; ASCORBIC ACID; BROMOCRIPTINE; CAFFEINE; CEP 1347; CREATININE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; PARKIN; PERGOLIDE; PESTICIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UBIDECARENONE; UNINDEXED DRUG;

BODY POSTURE; BRADYKINESIA; CELL DAMAGE; CELL DEATH; CLINICAL TRIAL; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG RESEARCH; DYSKINESIA; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; GENE MUTATION; GENETIC ANALYSIS; HUMAN; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; RIGIDITY; SYMPTOM; TREMOR;

EID: 3242665233     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043359585     Document Type: Review

References (241)

1. Ahlskog, J.E. (2003) Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology, 60, 381-9.
2. Ahlskog, J.E. and Muenter, M.D. (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord, 16, 448-58.
3. Aisen, P.S., Schafer, K.A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K.L., Farlow, M.R., Jin, S., Thomas, R.G., and Thal, L.J. (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 289, 2819-26.
4. Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Marsden, C.D., Jenner, P., and Halliwell, B. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem., 69, 1196-203.
5. Albin, R.L. and Frey, K.A. (2003) Initial agonist treatment of Parkinson disease: a critique. Neurology, 60, 390-4.
6. Albin, R.L. and Greenamyre, J.T. (1992) Alternative excitotoxic hypothesis. Neurology, 42, 733-738.
7. Allam, M.F., Del Castillo, A.S., and Navajas, R.F. (2003) Parkinson's disease, smoking and family history: meta-analysis. Eur. J. Neurol., 10, 59-62.
8. Ames, B.N., Shigenaga, M.K., and Hagen, T.M. (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA, 90, 7915-22.
9. Andreassen, O.A., Dedeoglu, A., Ferrante, R.J., Jenkins, B.G., Ferrante, K.L., Thomas, M., Friedlich, A., Browne, S.E., Schilling, G., Borchelt, D.R., Hersch, S.M., Ross, C.A., and Beal, M.F. (2001) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis., 8, 479-91.
10. Anglade, P., Vyas, S., Hirsch, E.C., and Agid, Y. (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol. Histopathol., 12, 603-10.
11. Arima, K., Ueda, K., Sunohara, N., Arakawa, K., Hirai, S., Nakamura, M., Tonozuka-Uehara, H., and Kawai, M. (1998) NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. (Berl.), 96, 439-44.
12. Ascherio, A., Chen, H., Schwarzschild, M.A., Zhang, S.M., Colditz, G.A., and Speizer, F.E. (2003) Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology, 60, 790-5.
13. Ascherio, A., Zhang, S.M., Hernan, M.A., Kawachi, I., Colditz, G.A., Speizer, F.E., and Willett, W.C. (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol., 50, 56-63.
14. Augood, S.J. (1999) Localization of adenosine A2A receptors in brain: therapeutic implications. Adv. Neurol, 80, 105-9.
15. Banati, R.B., Daniel, S.E., and Blunt, S.B. (1998) Glial pathology but absence of apoptotic nigral neurons in long- standing Parkinson's disease. Mov. Disord., 13, 221-7.
16. Beal, M.F. (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci., 23, 298-304.
17. Beal, M.F. (2002) Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med., 32, 797-803.
18. Beal, M.F. (2003) Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol., 53 Suppl. 3, S39-47; discussion S47-8.
19. Beal, M.F., Matthews, R.T., Tieleman, A., and Shults, C.W. (1998) Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res., 783, 109-14.
20. Benveniste, E.N. (1992) Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am. J. Physiol., 263, C1-16.
21. Betarbet, R., Sherer, T.B., Di Monte, D.A., and Greenamyre, J.T. (2002) Mechanistic approaches to Parkinson's disease. Brain Pathology, 12, 499-510.
22. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., and Greenamyre, J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 3, 1301-6.
23. Bjorklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C., and Mandel, R.J. (2000) Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res., 886, 82-98.
24. Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A.L., Sadoul, R., and Verna, J.M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol., 65, 135-72.
25. Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H., and Riederer, P. (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett., 202, 17-20.
26. Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 24, 197-211.
27. Brooks, D.J. (1998) The early diagnosis of Parkinson's disease. Ann. Neurol., 44, S10-8.
28. Brooks, D.J. (2003) Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann. Neurol., 53 Suppl. 3, S110-8; discussion S118-9.
29. Brouillet, E. and Beal, M.F. (1993) NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. NeuroRep., 4, 387-90.
30. Brouillet, E., Henshaw, D.R., Schulz, J.B., and Beal, M.F. (1994) Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10. Neurosci. Lett., 177, 58-62.
31. Cantuti-Castelvetri, I., Shukitt-Hale, B., and Joseph, J.A. (2000) Neurobehavioral aspects of antioxidants in aging. Int. J. Dev. Neurosci., 18, 367-81.
32. Chauhan, N.B., Siegel, G.J., and Lee, J.M. (2001) Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat., 21, 277-88.
33. Chen, H., Zhang, S.M., Hernan, M.A., Schwarzschild, M.A., Willett, W.C., Colditz, G.A., Speizer, F.E., and Ascherio, A. (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol., 60, 1059-64.
34. Chen, J.-F., Xu, K., Petzer, J.P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P.K., Castagnoli, K., Castagnoli, N., and Schwarzschild, M.A. (2001) Neuroprotection by caffiene and A2a adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci., 21, RC143 1-6.
35. Choi, D.W. and Rothman, S.M. (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci., 13, 171-182.
36. Chu, Y., Kompoliti, K., Cochran, E.J., Mufson, E.J., and Kordower, J.H. (2002) Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J. Comp. Neurol., 450, 203-14.
37. Conn, P.J. and Pin, J.P. (1997) Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharm. Tox., 37, 205-37.
38. Conway, K.A., Harper, J.D., and Lansbury, P.T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med., 4, 1318-20.
39. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Harper, J.D., Williamson, R.E., and Lansbury, P.T., Jr. (2000) Accelerated oligomerization by Parkinson's disease linked alpha- synuclein mutants. Ann. NY Acad. Sci., 920, 42-5.
40. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E., and Lansbury, P.T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA, 97, 571-6.
41. Conway, K.A., Rochet, J.C., Bieganski, R.M., and Lansbury, P.T., Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine- alpha-synuclein adduct. Science, 294, 1346-9.
42. Cotzias, G.C., Papavasiliou, P.S., and Gellene, R. (1969) Modification of parkinsonism - chronic treatment with L-DOPA. New Eng. J. Med., 280, 337-345.
43. Counihan, T.J., Landwehrmeyer, G.B., Standaert, D.G., Kosinski, C.M., Scherzer, C.R., Daggett, L.P., Velicelebi, G., Young, A.B., and Penney, J.B. (1998) Expression of N-methyl-D-aspartate receptor subunit mRNA in human mesencephalic dopamine neurons. J. Comp. Neurol., 390, 91-101.
44. Cummings, C.J. and Zoghbi, H.Y. (2000) Fourteen and counting: unraveling trinucleotide repeat diseases. Hum. Mol. Genet., 9, 909-16.
45. Damier, P., Kastner, A., Agid, Y., and Hirsch, E.C. (1996) Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology, 46, 1262-9.
46. Dawson, T.M. and Dawson, V.L. (2002) Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci., 5 Suppl., 1058-61.
47. de Rijk, M.C., Breteler, M.M., den Breeijen, J.H., Launer, L.J., Grobbee, D.E., van der Meche, F.G., and Hofman, A. (1997) Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch. Neurol., 54, 762-5.
48. Dedeoglu, A., Kubilus, J.K., Yang, L., Ferrante, K.L., Hersch, S.M., Beal, M.F., and Ferrante, R.J. (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem., 85, 1359-67.
49. Dexter, D.T., Wells, F.R., Agid, F., Agid, Y., Lees, A.J., Jenner, P., and Marsden, C.D. (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet, 2, 1219-20.
50. Di Monte, D.A., Chan, P., and Sandy, M.S. (1992) Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage? Ann. Neurol., 32, S111-5.
51. Diamond, S.G., Markham, C.H., Hoehn, M.M., McDowell, F.H., and Muenter, M.D. (1987) Multi-center study of parkinson mortality with early versus later dopa treatment. Ann. Neurol., 22, 8-12.
52. Dickson, D.W., Liu, W., Hardy, J., Farrer, M., Mehta, N., Uitti, R., Mark, M., Zimmerman, T., Golbe, L., Sage, J., Sima, A., D'Amato, C., Albin, R., Gilman, S., and Yen, S.H. (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol., 155, 1241-51.
53. Dingeldine, R., Borges, K., Bowie, D., and Traynelis, S.F. (1999) The glutamate receptor ion channels. Pharmacological Reviews, 51, 7-61.
54. Eddleston, M. and Mucke, L. (1993) Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience, 54, 15-36.
55. Elbaz, A., Bower, J.H., Peterson, B.J., Maraganore, D.M., McDonnell, S.K., Ahlskog, J.E., Schaid, D.J., and Rocca, W.A. (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch. Neurol., 60, 91-6.
56. Fahn, S. (1991) An open trial of high-dosage antioxidants in early Parkinson's disease. Am. J. Clin. Nutr., 53, 380S-382S.
57. Fahn, S. (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol., 32 Suppl., S128-32.
58. Favit, A., Nicoletti, F., Scapagnihi, U., and Canonico, P.L. (1992) Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration. J. Cereb. Blood Flow Metab., 12, 638-45.
59. Feany, M.B. and Bender, W.W. (2000) A Drosophila model of Parkinson's disease. Nature, 404, 394-8.
60. Fearnley, J. and Lees, A.(1994) Pathology of Parkinson's disease, In: Caine, D.B., Editor Neurodegenerative Diseases, W.B. Saunders: Philadelphia. pp. 545-571.
61. Ferrante, R.J., Browne, S.E., Shinobu, L.A., Bowling, A.C., Baik, M.J., MacGarvey, U., Kowall, N.W., Brown, R.H. Jr., and Beal, M.F. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem., 69, 2064-74.
62. Ferré, S., O'Connor, W.T., Fuxe, K., and Ungerstedt, U. (1993) The striatopallidal neuron: a main locus for adenosine -dopamine interactions in the brain. J. Neurosci., 13, 5402-5406.
63. Ferrer, I., Blanca, R., Carmona, M., Puig, B., Barrachina, M., Gomez, C., and Ambrosio, S. (2001) Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J. Neural. Transm., 108, 1383-96.
64. Finberg, J.P. and Youdim, M.B. (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacol., 43, 1110-8.
65. Finsterer, J. (2002) Parkinson syndrome as a manifestation of mitochondriopathy. Acta. Neurol. Scand., 105, 384-9.
66. Foltynie, T., Sawcer, S., Brayne, C., and Barker, R.A. (2002) The genetic basis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 73, 363-70.
67. Forsyth, R., Fray, A., Boutelle, M., Fillenz, M., Middleditch, C., and Burchell, A. (1996) A role for astrocytes in glucose delivery to neurons? Dev. Neurosci., 18, 360-70.
68. Fowler, J.S., Logan, J., Wang, G.J., and Volkow, N.D. (2003) Monoamine oxidase and cigarette smoking. Neurotoxicology, 24, 75-82.
69. Fowler, J.S., Volkow, N.D., Wang, G.J., Pappas, N., Logan, J., Shea, C., Alexoff, D., MacGregor, R.R., Schlyer, D.J., Zezulkova, I., and Wolf, A.P. (1996) Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. USA, 93, 14065-9.
70. Gash, D.M., Zhang, Z., and Gerhardt, G. (1998) Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol., 44, S121-5.
71. Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q., and Lee, V.M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron, 34, 521-33.
72. Giasson, B.I. and Lee, V.M. (2001) Parkin and the molecular pathways of Parkinson's disease. Neuron, 31, 885-8.
73. Gibb, W.R. (1992) Neuropathology of Parkinson's disease and related syndromes. Neurol. Clin., 10, 361-76.
74. Gibb, W.R. and Lees, A.J. (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 54, 388-96.
75. Gill, S.S., Patel, N.K., Horton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., and Heywood, P. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 9, 589-95.
76. Goedert, M. (1999) Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos. Trans. R Soc. Land. B Biol. Sci., 354, 1101-18.
77. Goedert, M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci., 2, 492-501.
78. Golbe, L.I., Farrell, T.M., and Davis, P.H. (1988) Case-control study of early life dietary factors in Parkinson's disease. Arch. Neurol., 45, 1350-3.
79. Golbe, L.I., Farrell, T.M., and Davis, P.H. (1990) Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov. Disord., 5, 66-70.
80. Goldberg, M.S. and Lansbury, P.T., Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol., 2, E115-9.
81. Gomez-Tortosa, E., Irizarry, M.C., Gomez-Isla, T., and Hyman, B.T. (2000) Clinical and neuropathological correlates of dementia with Lewy bodies. Ann. N Y Acad. Sci., 920, 9-15.
82. Grunblatt, E., Mandel, S., and Youdim, M.B. (2000) MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J. Neurol., 247 Suppl. 2, II95-102.
83. Gwinn-Hardy, K. (2002) Genetics of parkinsonism. Mov. Disord., 17, 645-56.
84. Hall, E.D., Andrus, P.K., Oostveen, J.A., Althaus, J.S., and VonVoigtlander, P.F. (1996) Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res., 742, 80-8.
85. Hastings, T.G., Lewis, D.A., and Zigmond, M.J. (1996) Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv. Exp. Med. Biol., 387, 97-106.
86. Hauser, R.A., Hubble, J.P., and Truong, D.D. (2003) Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology, 61, 297-303.
87. Hayakawa, M., Hattori, K., Sugiyama, S., and Ozawa, T. (1992) Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts. Biochem. Biophys. Res. Commun., 189, 979-85.
88. He, Y., Appel, S., and Le, W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res., 909, 187-93.
89. Hellenbrand, W., Boeing, H., Robra, B.P., Seidler, A., Vieregge, P., Nischan, P., Joerg, J., Oertel, W.H., Schneider, E., and Ulm, G. (1996) Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology, 47, 644-50.
90. Hellenbrand, W., Seidler, A., Boeing, H., Robra, B.P., Vieregge, P., Nischan, P., Joerg, J., Oertel, W.H., Schneider, E., and Ulm, G. (1996) Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology, 47, 636-43.
91. Hernan, M.A., Takkouche, B., Caamano-Isorna, F., and Gestal-Otero, J.J. (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol., 52, 276-84.
92. Hirsch, E.C. (2000) Glial cells and Parkinson's disease. J. Neurol., 247 Suppl .2, II58-62.
93. Hirsch, E.C., Hunot, S., Damier, P., Brugg, B., Faucheux, B.A., Michel, P.P., Ruberg, M., Muriel, M.P., Mouatt-Prigent, A., and Agid, Y. (1999) Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Adv. Neurol., 80, 9-18.
94. Hirsch, E.C., Hunot, S., Damier, P., and Faucheux, B. (1998) Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol., 44, S115-20.
95. Hornykiewicz, O. (1973) Dopamine in the basal ganglia. Br. Med. Bull., 29, 172-178.
96. Hornykiewicz, O. (2002) Dopamine miracle: From brain homogenate to dopamine replacement. Mov. Disord., 17, 501-8.
97. Hubble, J.P., Cao, T., Hassanein, R.E., Neuberger, J.S., and Koller, W.C. (1993) Risk factors for Parkinson's disease. Neurology, 43, 1693-7.
98. Hunot, S., Betard, C., Faucheaux, B., Agid, Y., and Hirsch, E.C. (1997) Immunohistochemical analysis of Intereferon-(gamma) and interleukin1-beta in the substantia nigra of Parkinsonian patients. Mov. Disord., 12, 20.
99. Hunot, S., Boissiere, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., and Hirsch, E.C. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience, 72, 355-63.
100. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-83.
101. Hurelbrink, C.B. and Barker, R.A. (2001) Prospects for the treatment of Parkinson's disease using neurotrophic factors. Expert Opin. Pharmacother., 2, 1531-43.
102. Irizarry, M.C., Growdon, W., Gomez-Isla, T., Newell, K., George, J.M., Clayton, D.F., and Hyman, B.T. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha- synuclein immunoreactivity. J. Neuropathol. Exp. Neurol., 57, 334-7.
103. Jellinger, K.A. (2000) Cell death mechanisms in Parkinson's disease. J. Neural. Transm., 107, 1-29.
104. Jenner, P. (2003) Oxidative stress in Parkinson's disease. Ann. Neurol., 53 Suppl. 3, S26-36; discussion S36-8.
105. Jenner, P. and Olanow, C.W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 47, S161-70.
106. Kann, M., Jacobs, H., Mohrmann, K., Schumacher, K., Hedrich, K., Garrels, J., Wiegers, K., Schwinger, E., Pramstaller, P.P., Breakefield, X.O., Ozelius, L.J., Vieregge, P., and Klein, C. (2002) Role of parkin mutations in 111 community-based patients with early- onset parkinsonism. Ann. Neurol., 51, 621-5.
107. Kasai, H. (1997) Analysis of a form of oxidative DNA damage, 8-hydroxy-2′- deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat. Res., 387, 147-63.
108. Kieburtz, K. (2003) Designing neuroprotection trials in Parkinson's disease. Ann. Neurol., 53 Suppl. 3, S100-7; discussion S107-9.
109. Kingsbury, A.E., Mardsen, C.D., and Foster, O.J. (1998) DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov. Disord., 13, 877-84.
110. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 329, 605-608.
111. Klivenyi, P., Ferrante, R.J., Matthews, R.T., Bogdanov, M.B., Klein, A.M., Andreassen, O.A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., and Beal, M.F. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med., 5, 347-50.
112. Knott, C., Stern, G., and Wilkin, G.P. (2000) Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci., 16, 724-39.
113. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N., and Aebischer, P. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290, 767-73.
114. Kreutzberg, G.W. (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci., 19, 312-8.
115. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 18, 106-8.
116. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med., 339, 1044-53.
117. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease. Second of two parts. N. Engl. J. Med., 339, 1130-43.
118. Lange, K.W., Rausch, W.D., Gsell, W., Naumann, M., Oestreicher, E., and Riederer, P. (1994) Neuroprotection by dopamine agonists. J. Neural. Transm. Suppl., 43, 183-201.
119. Langston, J.W. (1996) The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology, 47, S153-60.
120. Langston, J.W., Ballard, P., Tetrud, J.W., and Irwin, I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-80.
121. Lin, F.F., Varney, M., Sacaan, A.I., Jachec, C., Daggett, L.P., Rao, S., Flor, P., Kuhn, R., Kerner, J.A., Standaert, D., Young, A.B., and Velicelebi, G. (1997) Cloning and stable expression of the mGluR1b subtype of human metabotropic receptors and pharmacological comparison with the mGluR5a subtype. Neuropharmacol., 36, 917-31.
122. Lin, M.T., Simon, D.K., Ahn, C.H., Kim, L.M., and Beal, M.F. (2002) High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum. Mol. Genet., 11, 133-45.
123. Liou, H.H., Tsai, M.C., Chen, C.J., Jeng, J.S., Chang, Y.C., Chen, S.Y., and Chen, R.C. (1997) Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology, 48, 1583-8.
124. Logroscino, G., Marder, K., Cote, L., Tang, M.X., Shea, S., and Mayeux, R. (1996) Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol., 39, 89-94.
125. LoPachin, R.M., Jr. and Aschner, M. (1993) Glial-neuronal interactions: relevance to neurotoxic mechanisms. Toxicol. Appl. Pharmacol., 118, 141-58.
126. Luginger, E., Wenning, G.K., Bosch, S., and Poewe, W. (2000) Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord., 15, 873-8.
127. Lynch, D.R. and Guttmann, R.P. (2002) Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes. J. Pharmacol. Exp. Ther., 300, 717-23.
128. Magistretti, P.J. and Pellerin, L. (1996) Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann. NY Acad. Sci., 777, 380-7.
129. Malcon, C., Kaddurah-Daouk, R., and Beal, M.F. (2000) Neuroprotective effects of creative administration against NMDA and malonate toxicity. Brain Res., 860, 195-8.
130. Manning-Bog, A.B., McCormack, A.L., Li, J., Uversky, V.N., Fink, A.L., and Di Monte, D.A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha- synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem., 277, 1641-4.
131. Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., Oakes, D., and Seibyl, J. (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology, 57, 2089-94.
132. Marek, K., Jennings, D., and Seibyl, J. (2003) Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann. Neurol., 53 Suppl. 3, S160-6; discussion S166-9.
133. Martyn, C. (2003) Anti-inflammatory drugs and Alzheimer's disease. Brit. Med. J., 327, 353-4.
134. Maruyama, W., Yamamoto, T., Kitani, K., Carrillo, M.C., Youdim, M., and Naoi, M. (2000) Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev., 116, 181-91.
135. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in alpha synuclein mice: implications for neurodegenerative disorders. Science, 287, 1265-9.
136. Mattammal, M.B., Strong, R., Lakshmi, V.M., Chung, H.D., and Stephenson, A.H. (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J. Neurochem., 64, 1645-54.
137. Matthews, R.T., Ferrante, R.J., Klivenyi, P., Yang, L., Klein, A.M., Mueller, G., Kaddurah-Daouk, R., and Beal, M.F. (1999) Creative and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol., 157, 142-9.
138. Mattson, M.P. (2003) Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med., 3, 65-94.
139. Mecocci, P., MacGarvey, U., and Beal, M.F. (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol., 36, 747-51.
140. Mecocci, P., MacGarvey, U., Kaufman, A.E., Koontz, D., Shoffner, J.M., Wallace, D.C., and Beal, M.F. (1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol., 34, 609-16.
141. Mirza, B., Hadberg, H., Thomsen, P., and Moos, T. (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience, 95, 425-32.
142. Mizuno, Y., Hattori, N., Mori, H., Suzuki, T., and Tanaka, K. (2001) Parkin and Parkinson's disease. Curr. Opin. Neurol., 14, 477-82.
143. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., and Nagatsu, T. (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett., 180, 147-50.
144. Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., and Nagatsu, T. (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett., 270, 45-8.
145. Mohanakumar, K.P., Muralikrishnan, D., and Thomas, B. (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res., 864, 281-90.
146. Muhkin, A., Fan, L., and Faden, A.I. (1996) Activation of metabotropic glutamate receptor subtype mGluR1 contributes to post-traumatic neuronal injury. J. Neurosci., 16, 6012-6020.
147. Murray, T.K., Messenger, M.J., Ward, M.A., Woodhouse, S., Osborne, D.J., Duty, S., and O'Neill, M.J. (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol. Biochem. Behav., 73, 455-66.
148. Nagatsu, T., Mogi, M., Ichinose, H., and Togari, A. (2000) Cytokines in Parkinson's disease. J. Neural. Transm. Suppl., 58, 143-51.
149. Neff, F., Noelker, C., Eggert, K., and Schlegel, J. (2002) Signaling pathways mediate the neuroprotective effects of GDNF. Ann. NY Acad. Sci., 973, 70-4.
150. Nicoletti, F., Bruno, V., Catania, M.V., Battaglia, G., Copani, A., Barbagallo, G., Ceña, V., Sanchez-Prieto, J., Spano, P.F., and Pizzi, M. (1999) Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacol, 38, 1477-1484.
151. Nicoletti, F., Bruno, V., Copani, A., Casabona, G., and Knopfel, T. (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci., 19, 267-71.
152. Nutt, J.G., Burchiel, K.J., Comella, C.L., Jankovic, J., Lang, A.E., Laws, E.R., Jr., Lozano, A.M., Penn, R.D., Simpson, R.K. Jr., Stacy, M., and Wooten, G.F. (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology, 60, 69-73.
153. Obeso, J.A., Olanow, C.W., and Nutt, J.G. (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci., 23, S2-7.
154. Olney, J.W. (1969) Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science, 164, 719-721.
155. Papp, M.I., Kahn, J.E., and Lantos, P.L. (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci., 94, 79-100.
156. Parker, W.D., Jr. and Swerdlow, R.H. (1998) Mitochondrial dysfunction in idiopathic Parkinson disease. Am. J. Hum. Genet., 62, 758-762.
157. Parkinson Study Group (1989) Effect of deprenyl on the progression of disablity in early Parkinson's disease. New Eng. J. Med., 321, 1364-71.
158. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in Parkinson's disease. New Eng. J. Med., 328, 176-183.
159. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA, 284, 1931-8.
160. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol., 59, 1937-43.
161. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 287, 1653-61.
162. Paulson, H.L. and Fischbeck, K.H. (1996) Trinucleotide repeats in neurogenetic disorders. Annu. Rev. Neurosci., 19, 79-107.
163. Pelligrini-Giampietro, D.E., Peruginelli, F., Meli, E., Cozzi, A., Albani-Torregrossa, S., Pellicciari, R., and Moroni, F. (1999) Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time course and mechanisms. Neuropharmacol., 38, 1607-1620.
164. Perry, T.L., Godin, D.V., and Hansen, S. (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett., 33, 305-10.
165. Perry, T.L. and Yong, V.W. (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett., 67, 269-74.
166. Piani, D., Frei, K., Do, K.Q., Cuenod, M., and Fontana, A. (1991) Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci. Lett., 133, 159-62.
167. Polymeropoulos, M.H., Levedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Pappetropoulso, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., and Nussbaum, R.L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
168. Prusiner, S.B. (1998) Prions. Proc. Natl. Acad. Sci. USA, 95, 13363-13383.
169. Rajput, A.H., Fenton, M.E., Birdi, S., Macaulay, R., George, D., Rozdilsky, B., Ang, L.C., Senthilselvan, A., and Hornykiewicz, O. (2002) Clinical-pathological study of levodopa complications. Mov. Disord., 17, 289-96.
170. Ramirez, A.D., Wong, S.K., and Menniti, F.S. (2003) Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur. J. Pharmacol., 475, 29-35.
171. Rascol, O. (2000) Medical treatment of levodopa-induced dyskinesias. Ann. Neurol., 47, S179-88.
172. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., and Lang, A.E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med., 342, 1484-91.
173. Ravina, B.M., Fagan, S.C., Hart, R.G., Hovinga, C.A., Murphy, D.D., Dawson, T.M., and Marler, J.R. (2003) Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment. Neurology, 60, 1234-40.
174. Richter, C., Park, J.W., and Ames, B.N. (1988) Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. USA, 85, 6465-7.
175. Riederer, P., Dirr, A,, Goetz, M., Sofic, E., Jellinger, K.,
176. Riederer, P., Sofic, E., Rausch, W.D., Schmidt, B., Reynolds, G.P., Jellinger, K., and Youdim, M.B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J . Neurochem., 52, 515-20.
177. Ritz, B. and Yu, F. (2000) Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int. J. Epidemiol., 29, 323-9.
178. Rochet, J.C., Conway, K.A., and Lansbury, P.T., Jr. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry, 39, 10619-26.
179. Rodriguez, M.C., Obeso, J.A., and Olanow, C.W. (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol., 44, S175-88.
180. Ross, G.W., Abbott, R.D., Petrovitch, H., Morens, D.M., Grandinetti, A., Tung, K.H., Tanner, C.M., Masaki, K.H., Blanchette, P.L., Curb, J.D., Popper, J.S., and White, L.R. (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA, 283, 2674-9.
181. Sanchez-Ramos, R.R., Overvik, E., and Ames, B.N. (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2′ -deoxyguanosine) is increased in nigro-striatum of Parkinson's disease. Neurodegeneration, 3, 197-204.
182. Saporito, M.S., Brown, E.M., Miller, M.S., and Carswell, S. (1999) CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol Exp. Ther., 288, 421-7.
183. Sapp, E., Schwarz, C., Chase, K., Bhide, P.G., Young, A.B., Penney, J., Vonsattel, J.P., Aronin, N., and DiFiglia, M. (1997) Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol., 42, 604-12.
184. Schapira, A.H. (2002) Neuroprotection and dopamine agonists. Neurology, 58, S9-18.
185. Schapira, A.H., Gu, M., Taanman, J.W., Tabrizi, S.J., Seaton, T., Cleeter, M., and Cooper, J.M. (1998) Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol., 44, S89-98.
186. Schapira, A.H., Mann, V.M., Cooper, J.M., Krige, D., Jenner, P.J., and Marsden, C.D. (1992) Mitochondrial Function in Parkinson's disease. Ann. Neurol., 32, S116-24.
187. Scheider, W.L., Hershey, L.A., Vena, J.E., Holmlund, T., Marshall, J.R., and Freudenheim (1997) Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov. Disord., 12, 190-6.
188. 2 receptors regulate the gene expresion of striatopallidal and striatonigral neurons. J. Neurosci., 13, 1080-1087.
189. Schoepp, D.D. (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther., 299, 12-20.
190. Schoepp, D.D., Jane, D.E., and Monn, J.A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacol., 38, 1431-1476.
191. Schwarz, S.C., Schwarz, J., Sautter, J., and Oertel, W.H. (1998) Effects of macrophage migration inhibitory factor and macrophage migration stimulatory factor on function and survival of foetal dopaminergic grafts in the 6-hydroxydopamine rat model of Parkinson's disease. Exp. Brain Res., 120, 95-103.
192. Schwarzschild, M.A., Chen, J.F., and Ascherio, A. (2002) Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology, 58, 1154-60.
193. Selkoe, D.J. (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol., 8, 447-53.
194. Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., Panov, A.V., Cookson, M.R., and Greenamyre, J.T. (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci., 22, 7006-15.
195. Sherer, T.B., Kim, J.-H., Betarbet, R., and Greenamyre, J.T. (2003) Subcutanteous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol., 179, 9-16.
196. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., and Suzuki, T. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet., 25, 302-5.
197. Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K.S., and Selkoe, D.J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293, 263-9.
198. Shimura-Miura, H., Hattori, N., Kang, D., Miyako, K., Nakabeppu, Y., and Mizuno, Y. (1999) Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann. Neurol., 46, 920-4.
199. Shoulson, I. (1998) DATATOP: a decade of neuroprotective inquiry. Ann. Neurol., 44, S160-6.
200. Shoulson, I. (1998) Where do we stand on neuroprotection? Where do we go from here? Mov. Disord., 13 Suppl. 1, 46-8.
201. Shults, C.W., Haas, R.H., Passov, D., and Beal, M.F. (1997) Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol., 42, 261-4.
202. Shults, C.W., Oakes, D., Kieburtz, K., Beal, M.F., Haas, R., Plumb, S., Juncos, J.L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., Perlmutter, J.S., Reich, S., Stern, M., Watts, R.L., Kurlan, R., Molho, E., Harrison, M., and Lew, M. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol., 59, 1541-50.
203. Siegel, G.J. and Chauhan, N.B. (2000) Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Brain Res. Rev., 33, 199-227.
204. Simantov, R. (1989) Glutamate neurotoxicity in culture depends on the presence of glutamane: implications for the role of glial cells in normal and pathological brain development. J. Neurochem., 52, 1694-9.
205. Simon, D.K. and Johns, D.R. (1999) Mitochondrial disorders: clinical and genetic features. Annu. Rev. Med., 50, 111-27.
206. Simon, D.K., Lin, M.T., and Pascual-Leone, A. (2002) 'Nature vs nurture' and incompletely penetrant mutations: lessons from twin studies of Parkinson's disease. J. Neurol. Neurosurg. Psych., 72, 686-9.
207. Simon, D.K., Pulst, S.M., Sutton, J.P., Browne, S.E., Beal, M.F., and Johns, D.R. (1999) Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology, 53, 1787-93.
208. Singleton, A., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) Alpha-Synuclein locus triplication causes Parkinson disease. Science, 302, 841.
209. Sofic, E., Lange, K.W., Jellinger, K., and Riederer, P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett., 142, 128-30.
210. Spillantini, M.G., Crowther, R.A., Jakes, R., Cairns, N.J., Lantos, P.L., and Goedert, M. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett., 251, 205-8.
211. Spillantini, M.G. and Goedert, M. (2000) The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. NY Acad. Sci., 920, 16-27.
212. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-40.
213. Standaert, D.G. and Young, A.B. (2001) Treatment of Central nervous System Degenerative Disorders, In: Hardman, J.G. and Limbird, L.E., Editors, Goodman and Gilman's Pharmacological Basis of Therapeutics, Tenth Edition, McGraw-Hill, pp. 549-620.
214. Stocchi, F. and Olanow, C.W. (2003) Neuroprotection in Parkinson's disease: clinical trials. Ann. Neurol., 53 Suppl. 3, S87-97; discussion S97-9.
215. Stoof, J.C., Booij, J., Drukarch, B., and Wolters, E.C. (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur. J. Pharm., 213, 439-43.
216. Svenningsson, P., Le Maine, C., Aubert, I., Burbaud, P., Fredholm, B.B., and Bloch, B. (1998) Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J. Comp. Neurol., 399, 229-40.
217. Takeda, A., Mallory, M., Sundsmo, M., Honer, W., Hansen, L., and Masliah, E. (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol., 152, 367-72.
218. Tanaka, J., Toku, K., Zhang, B., Ishihara, K., Sakanaka, M., and Maeda, N. (1999) Astrocytes prevent neuronal death induced by reactive oxygen and nitrogen species. Glia, 28, 85-96.
219. Tanner, C.M. (1992) Epidemiology of Parkinson's disease. Neurol. Clin., 10, 317-29.
220. Tanner, C.M., Goldman, S.M., Aston, D.A., Ottman, R., Ellenberg, J., Mayeux, R., and Langston, J.W. (2002) Smoking and Parkinson's disease in twins. Neurology, 58, 581-8.
221. Tanner, C.M., Ottman, R., Goldman, S.M., Ellenberg, J., Chan, P., Mayeux, R., and Langston, J.W. (1999) Parkinson disease in twins: an etiologic study. JAMA, 281, 341-6.
222. Tatton, N.A. (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol., 166, 29-43.
223. Taylor, D.L., Diemel, L.T., and Pocock, J.M. (2003) Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J. Neurosci., 23, 2150-60.
224. Teismann, P. and Ferger, B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse, 39, 167-74.
225. Teismann, P., Vila, M., Choi, D.K., Tieu, K., Wu, D.C., Jackson-Lewis, V., and Przedborski, S. (2003) COX-2 and neurodegeneration in Parkinson's disease. Ann. N.Y. Acad. Sci., 991, 272-7.
226. Tikka, T., Fiebich, B.L., Goldsteins. G., Keinanen, R., and Koistinaho, J. (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci., 21, 2580-8.
227. Ugarte, S.D., Lin, E., Klann, E., Zigmond, M.J., and Perez, R.G. (2003) Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J. Neurosci. Res., 73, 105-12.
228. Uitti, R., Rajput, A., Ahlskog, J., Offord, K., Schroeder, D., Ho, M., Prasad, M., Rajput, A., and Basran, P. (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology, 46, 1551-1556.
229. Wakabayashi, K., Matsumoto, K., Takayama, K., Yoshimoto, M., and Takahashi, H. (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett., 239, 45-8.
230. Wakabayashi, K., Yoshimoto, M., Tsuji, S., and Takahashi, H. (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett., 249, 180-2.
231. Weisskopf, M.G., Chen, H., Schwarzschild, M.A., Kawachi, I., and Ascherio, A. (2003) Prospective study of phobic anxiety and risk of Parkinson's disease. Mov. Disord., 18, 646-51.
232. Whone, A.L., Watts, R.L., Stoessl, A.J., Davis, M., Reske, S., Nahmias, C., Lang, A.E., Rascol, O., Ribeiro, M.J., Remy, P., Poewe, W.H., Hauser, R.A., and Brooks, D.J. (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol., 54, 93-101.
233. Wolozin, B. and Behl, C. (2000) Mechanisms of neurodegenerative disorders: Part 1: protein aggregates. Arch. Neurol., 57, 793-6.
234. Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.K., Ischiropoulos, H., and Przedborski, S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci., 22, 1763-71.
235. Wullner, U., Kornhuber, J., Weller, M., Schulz, J.B., Loschmann, P.A., Riederer, P., and Klockgether, T. (1999) Cell death and apoptosis regulating proteins in Parkinson's disease-a cautionary note. Acta Neuropathol. (Berl.), 97, 408-12.
236. Xia, X.G., Harding, T., Weller, M., Bieneman, A., Uney, J.B., and Schulz, J.B. (2001) Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 98, 10433-8.
237. Yang, L., Sugama, S., Chirichigno, J.W., Gregorio, J., Lorenzl, S., Shin, D.H., Browne, S.E., Shimizu, Y., Joh, T.H., Beal, M.F., and Albers, D.S. (2003) Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res., 74, 278-85.
238. Yong, V.W. and Perry, T.L. (1986) Monoamine oxidase B, smoking, and Parkinson's disease. J. Neurol. Sci., 72, 265-72.
239. Youdim, M.B. and Weinstock, M. (2001) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol. Neurobiol., 21, 555-73.
240. Yrjanheikki, J., Tikka, T., Keinanen, R., Goldsteins, G., Chan, P.H., and Koistinaho, J. (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA, 96, 13496-500.
241. Zhang, Y., Gao, J., Chung, K.K., Huang, H., Dawson, V.L., and Dawson, T.M. (2000) Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA, 97, 13354-9.